Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — FY2010 Earnings Presentation
71 slides from Aspen Pharmacare's earnings presentation, September 2010
Slide 1: Group Annual Results
e) aspen H O L Dt N G S Group Annual Results
Slide 2: 2010 Results Highlights
2010 RESULTS HIGHLIGHTS Turnover exceeds R10 billion Headline Earnings +39% perating Cash Flow per share 40% apital Distribution 70 cents per hare 2
Slide 3: Compound Annual Growth Rate
COMPOUND ANNUAL GROWTH RATE Revenue Growth Since EBITA Growth Since Inception Inception Revenue – R’millions EBITA – R’millions 2,717 10,147 2,270 8,441 4,682 1,1981,314 3,4494,026 833 987 2,815 632 1,8902,202 416 501 353 936 1,0041,561 211 300 73 14 72 998 999 000 001 002 003 004 005 006 007 008 00
Slide 4: Income Statement Re-analysed
INCOME STATEMENT RE-ANALYSED Year ended Year ended % June 2010 June 2009 Chang R’m R’m e Continuing Operations Revenue 10 147 8 441 +20% Gross Profit 4 604 3 877 +19% Net operating expenses (1 887) (1 607) EBITA 2 717 2 270 +20% Amortisation (102) (95) Operating profit 2 615 2 175 +20% Net funding c
Slide 5: Revenue and EBITA by Segment
REVENUE AND EBITA BY SEGMENT June 2010 : Revenue - R10.6bn June 2010 : *EBITA : R2.8bn SSA 3% SSA 9% Internation Internation al al39% 38% South Africa South 53% Africa 58% June 2009 : Revenue - R8.4bn June 2009 : *EBITA : R2.3bn SSA 8% SSA 11% International International 38% 44% South Africa South A
Slide 6: Analysis of Segmental Revenue
ANALYSIS OF SEGMENTAL REVENUE * Revenue by Customer Geography R10.6 billion (2009 : R8.4 billion) 5,652 4,309 R’millions 1,468 1,435 1,234 1,150 1,144 910 931 822 South Africa Sub-Saharan Asia Pacific Latin America Rest of the World Africa 2010 2009 * Represents revenue from the sale of domestic and
Slide 7: Analysis of Revenue from Global Brands
ANALYSIS OF REVENUE FROM GLOBAL BRANDS Revenue from Global Brands R2.0 billion (2009 : R1.5 billion) 1,036 772 R’millions 453 319 337 303 100 72 82 45 South Africa Asia Pacific Latin America EMENAC Rest of the World 2010 2009 7
Slide 8: Segmental EBITA%
SEGMENTAL EBITA% Year Year ended ended June 2010 June 2009 South Africa 28% * 26% Sub-Saharan Africa 8% 19% International 28% 32% Group 27% * 27% *EBITA percentages has been normalised to exclude compensation for loss of profits received from insurers in respect of Aspen Nutritionals Analysis of EBI
Slide 9: Funding Costs
FUNDING COSTS Net Funding Costs 615 2010 2009 553 475 370 R'millions Notional interest on financial instruments Forex & fair value (gains)/losses 53 28 38 -4 -7 -19 Interest income -188 -224 Interest expense Preference dividend Net funding costs 9
Slide 10: Abridged Balance Sheet
ABRIDGED BALANCE SHEET Year ended Year ended June 2010 June 2009 Assets R’m R’m Non-current assets 12 178 6 921 Tangible fixed assets 3 012 2 374 Goodwill 456 398 Intangible assets 8 610 4 104 Other non-current assets 100 45 Current assets 4 683 3 536 Cash 2 940 2 065 19 801 12 522 Equity and Liabil
Slide 11: Capex Investment Trend
CAPEX INVESTMENT TREND Investment in Tangible Assets R2.1 billion over five years 627 632 R'millions 379 288 169 2006 2007 2008 2009 2010 11
Slide 12: Abridged Cash Flow Statement
ABRIDGED CASH FLOW STATEMENT Year ended Year ended June 2010 June 2009 R’m R’m Cash operating profit 3 269 2 668 Working capital requirements (344) (508) Cash generated from operations 2 925 2 160 Net finance costs paid (609) (759) Investment income received 182 224 Tax paid (465) (333) Net inflow f
Slide 13: Key Liquidity Ratios
KEY LIQUIDITY RATIO Net Debt & Operating Cash Flow Trend KEY LIQUIDITY RATIOS Net cash flow from operating activities Net Debt 4,039 3,019 R'millions 2,011 2,034 1,292 1,032 968 652 709 402 2006 2007 2008 2009 2010 29% 40% 24% 38% 49% 51% 60% 62% 71% 76% Debt Equity 13
Slide 14: Corporate Activities: Completion of GSK Transactions
CORPORATE ACTIVITIES ember 2009 : Completion of GSK Transactions • Series of interdependent strategic transactions • South Africa, Sub-Saharan Africa, Global Brands, Bad Oldesloe • 68.5 million shares issued to GSK • Transaction value of R4.6 billion • Successfully integrated 14
Slide 15: Corporate Activities: Sale of Campos
CORPORATE ACTIVITIES rch 2010 : Announcement of Sale of Campos • Agreement reached to sell the Campos manufacturing facility plus products from Strides • Part of restructuring plan for business in Brazil • Exit from tender market products, contract manufacture • Risks and rewards transferred to Stri
Slide 16: Corporate Activities: Restructure of Oncology Arrangements
CORPORATE ACTIVITIES h 2010 : Announcement of Restructure of Oncology Arrangements • Sale of 50% shareholding in oncology joint ventures to Strides for USD117 million • License for existing and future oncology products secured for specified territories • Alignment with Aspen business model • Onco Th
Slide 17: Corporate Activities: Purchase of Sigma Pharmaceuticals
CORPORATE ACTIVITIES t 2010 : Announcement regarding purchase of Sigma Pharmaceuticals • Largest listed pharma business in Australia • Pharma sales > AUD600 million • Support of Sigma Board • Purchase consideration AUD900 million • Funded by cash and debt • Synergies with Aspen Australia, growth pla
Slide 18: Distribution of Fund Managers
DISTRIBUTION OF FUND MANAGERS As at 30 June 2010 As at 30 June 2009 Asia Asia Other Pacific Pacific Other 1% 1% 2% 2% South Africa South Africa Europe 43% Europe 59% 25% 15% North America North America 23% 29% 18
Slide 19: Corporate Activity: Environment and CSI
CORPORATE ACTIVITY • Environmental Management • Resource conservation initiatives are in place to save on and optimise energy and water consumption • Waste management protocols are applied to ensure responsible disposal of harmful substances • Recycling initiatives are in place • Corporate Social In
Slide 20: Corporate Activity: Employees and Sustainability
CORPORATE ACTIVITY • Employees • The Group provides secure employment to more than 6 000 employees • More than 50% of the employees received training during the year • On-site clinics provide a wide range of health checks, HIV/AIDS counselling and employee support as well as healthcare awareness pro
Slide 21: Aspen Group Headlines
ASPEN GROUP Headlines • Financial Highlights • South Africa major contributor • International impressive • Consider Rand strength • Aspen cash generating machine • Resumption of capital distribution • Strong currency hedge • Import component in South Africa matched by international income • South Af
Slide 22: Aspen Amongst Its Peer Group: Market Cap and EBITDA
ASPEN AMONGST ITS PEER GROUP 7.8 Market Capitalisation and Enterprise Value 7.1 Comparatives Market Cap-September 2010 EV 2010 5.3 5.4 5.8 5.3 5.1 5.3 USD' billion 4.1 3.4 2.9 3.0 2.4 2.5 1.5 1.4 0.4 0.4 Sun Cipla Aspen Dr Reddy Gideon Krka Hikma Adcock Cipla Pharma (India) Richter Medpro Informatio
Slide 23: Aspen Amongst Its Peer Group: Revenue
ASPEN AMONGST ITS PEER GROUP Information as per Citibank September 2010 Valuations for all companies except for Krka and Gideon Richter which are per Morgan Stanley September valuations Revenue Comparatives 1.8 1.8 REVENUE 2010F REVENUE 2011F 1.5 USD'billion 1.3 1.3 1.4 1.3 1.4 1.3 1.2 1.1 0.9 0.7 0
Slide 24: Aspen Amongst Its Peer Group: P/E and HEPS
ASPEN AMONGST ITS PEER GROUP Information as per Citibank September 2010 Valuations for all companies except for Krka and Gideon Richter which are per Morgan Stanley September valuations Price : Earning Comparatives PE 2010F PE 2011F 25.0 23.3 22.8 22.1 19.4 19.8 19.8 17.7 17.0 16.2 13.3 14.0 13.1 14
Slide 25: Aspen in the South African Market
ASPEN IN THE SOUTH AFRICAN MARKET harma Market MAT Rand Share % as per IMS – June 2010 Aspen/GSK Adock Ingram Sanofi-Aventis Pfizer Novartis AstraZeneca Cipla Medpro Merck & Co 16.4 16.5 16.2 16.1 16.1 16.2 16.2 16.2 16.1 16.3 16.3 16.3 16 GSK consolidated 14 retrospectively 12 10.0 10.0 10.0 10.0 1
Slide 26: Aspen in the South African Market
ASPEN IN THE SOUTH AFRICA MARKET • Retained market leadership in South Africa • Number 1 in public and private sectors • Nearly 1 in 4 of every tablet / capsule dispensed is for an Aspen product • Sales • Pharma by 40% • Consumer by 5% • Operating Income • Pharma by 56% • Consumer by 12% •
Slide 27: South African Private Market
ASPEN IN THE SOUTH AFRICAN PRIVATE MARKET r of Script Lines Dispensed : Source ImpactRx July 2010 Manufacturer Scripts % Share Aspen/GSK 28,532,828 24.1% Adcock Ingram 17,375,160 14.7% Novartis 7,581,336 6.4% 30,000,000 Almost 1 in 4 script lines Cipla 7,542,030 6.3% dispensed in the South African R
Slide 28: South African Public Market
ASPEN IN THE SOUTH AFRICAN PUBLIC MARKET 9 Oral Solid Dosage Tender (excludes ARVs) Daiichi Sankyo 3% Cipla 3% Sandoz 2% Dezzo 2% Pharmache Biogaran 5% m 2% Aspen/GSK Adcock 3% 30% Biotech 2% Gulf Drug 4% 2009 Aspen Other 24% 32% Multinationa ls 19% Other 25% 2001 MSD 8% Pharmaci a 3% Adcock 3% Serv
Slide 29: South African Public Market: Driving Cost Reductions
ASPEN IN THE SOUTH AFRICAN PUBLIC MARKET African Operations – Driving Cost Reductions olume key driver Economies of scale driving efficiencies eavy investment in infrastructure already made +16% Smaller capex investment to drive capacity enhancements +39% Unit 1 OSD increase in annual recoveries +78
Slide 30: South African Market Operations
SOUTH AFRICAN MARKET Operations • In last year OSD • Inspected / re-inspected by FDA, WHO and ANVISA (Brazil) • No significant findings • Worked tirelessly • Process improvements • Decreased drying time ten fold • Campaigned and increased batch size • Increased volumes • Saved change over times • Sa
Slide 31: South African Public Market: ARV Tender
ASPEN IN THE SOUTH AFRICAN PUBLIC MARKET ARV Tender • High value • Low margin • Have capacity – absorbs facility overheads • Tendered competitively • Demonstrated capability • Responsive to unpredictable volume shifts • Reliable supplier • Expect tender to commence in November • High risk tender • I
Slide 32: South African Market Performance
THE SOUTH AFRICAN MARKET PERFORMANCE ate Market as at June 2010 R21.97bn as per IMS (June 2009 – TPM R19.93bn) OTC R2.8bn OTC 2001 R6.0b n Generic R1.2bn Ethical/Branded R5.4 bn 2010 Growth from 2001 to 2010 Generi c OTC growth 115% Ethical/ R4.5b Branded Branded growth n R11.5 bn 113% Generic growt
Slide 33: Market Performance: Private Market Growth
THE MARKET PERFORMANCE African Private Market Growth as per IMS – June 2010 MARKET ASPEN +10.2 +12.7 Total % % +14.0 +11.0 Generic % % +8.7 +8.4 OTC % % +10.0 +19.0 Branded % % 33
Slide 34: South African Market
SOUTH AFRICAN MARKET • Defensive and resilient • Growth continues • Generics lead the way • World Cup disappointing • Public and private costs hard to contain in South African and emerging markets • Population growth • Growing affluences • Ageing population • Infectious diseases – young are also sic
Slide 35: South African Market
SOUTH AFRICAN MARKET • South African single exit price is fixed in Rands • Operating margins affected by currency volatility • Import cost component • Government focus on NHI • Implementation process not clear • All of the above is forcing a shift to affordability and generic usage • However quali
Slide 36: South African Generic Market Share
SOUTH AFRICAN MARKET Generic Market MAT Rand Share % as per IMS – June 2010 Daiichi Sankyo 3.9% Pfizer 3.4% Lupin Labs 4.3% Aspen 33.9% Adcock 10.2% Novartis 9.5% Other 16.4% Cipla 18.4% Big slice of a growing pie 36
Slide 37: South African Market: Generic Market
SOUTH AFRICAN MARKET Generic Market • Generics have a 27.9% value share • Generics have a 60.9% of counting units • Continues to outpace the overall market • Anticipate this trend to continue • Fragmented market • Numerous entrants • Highly competitive • Key drivers • Patent expirations • Affordabil
Slide 38: South African Market: Generic Market Leadership
SOUTH AFRICAN MARKET Generic Market • Aspen retained leadership position • Trench welfare • Strong competition – competitors agile • Limited acquisitive opportunities • Focus • Provide service • Provide unrivalled range of quality products • A-Z one stop shop • Manage complexity well • We have the b
Slide 39: Branded Market Rand Share
SOUTH AFRICAN MARKET randed Market MAT Rand Share % as per IMS – June 2010 Sanofi-Aventis Aspen/GSK AstraZeneca Pfizer Merck & Co Novartis Roche Adcock/Parke Med 13 12.52 12.30 12.32 12.39 12.36 12.35 12.40 12.35 12.19 12.24 12.28 12.16 12 10.96 11 10.78 10.58 10.57 10.67 10.38 10.44 10.44 10.20 10.
Slide 40: Branded Market Monthly Value Share
SOUTH AFRICAN MARKET anded Market Monthly Value Share % as per IMS – June 2010 Sanofi Aventis Aspen/GSK AstraZeneca Pfizer Merck & Co Novartis Roche Adcock/Parke Med 16 15 14.7 14 13.0 12.8 13 12.8 12.6 12.6 12.4 12.4 12.3 12.1 12 11.6 11.7 11.4 11.4 10.9 11.0 11 10.8 10.8 10.8 10.6 10.5 10.3 10.3 1
Slide 41: Branded Division
SOUTH AFRICAN MARKET randed Division • Largest value component of the South African market • Challenging for number 1 spot • Already! • Commercial capability already demonstrated • GSK’s innovation and Aspen’s commercial expertise • Risks – patented products under generic threat • Truvada and Sereti
Slide 42: OTC Market Share 1999-2001
SOUTH AFRICAN MARKET C Market June 1999 – June 2001 Adcock Aspen GSK Janssen Novartis Reckitt Benkiser 40 35 33.6 30.1 30 27.4 25 20 15 11.8 10.4 9.7 10 5.4 5.7 5.8 5 4.3 4.1 3.9 3.3 3.6 3.1 0 Mat Jun-99 Mat Jun-00 Mat Jun-01 42
Slide 43: OTC Market Rand Share
SOUTH AFRICAN MARKET e OTC Market MAT Rand Share % as per IMS – June 2010 Adcock Ingram Aspen Johnson & Johnson Sanofi-Aventis Pfizer Cipla Medpro Novartis 19.5 19.5 19.0 19.1 19.2 18.7 18.7 18.7 18.8 18.9 18.9 19 18.4 17 15.5 15.5 15.5 15.7 15.5 15.5 15.5 15.6 15.5 15.5 15.4 15.4 15 13 11 9 7.6 7.6
Slide 44: OTC / Consumer
SOUTH AFRICAN MARKET OTC / Consumer • OTC Market • Growth has been disappointing • Expected self medication • Tougher times • Effect of private labels? • Steadily grown OTC market share over time • Laxatives / Slimming • Unable to recover market share losses • Competition is fierce • Interesting p
Slide 45: Pharmacy Managed Healthcare Survey
SOUTH AFRICAN MARKET cted from Campbell Belman Survey – June 2010 An evaluation of the major prescription Pharmaceutical Companies in South Africa amongst top retail pharmacy outlets in major metropolitan areas 201 200 0 9 Pharmacy 1 2 Managed 1 5 Healthcare OTC 2 1 45
Slide 46: Campbell Belman Survey: Perceptions
0 10 20 30 40 50 60 70 80 90 Is financially sound & secure Has a strong cash flow Has clearly defined objective/strategy Adcock Ingram Is a well managed company Is reputable, honest and trustworthy SOUTH AFRICAN MARKET Believes in Aspen full disclosure Makes effective use of capital Co. reports refl
Slide 47: Campbell Belman Survey: Perceptions
0 10 20 30 40 50 60 70 80 90 Feel confident in its long term future Chief executive is a straight talker Communicates well with the investors Adcock Ingram Senior management accessible Strong growth potential Maintains balance SOUTH AFRICAN MARKET between risk & return Aspen Company results match ex
Slide 48: South African Market Summary
ASPEN IN THE SOUTH AFRICAN MARKET Summary • Results underpinned by • Strong Rand • Buoyant demand • Strong cash flows • Operational efficiencies • Team determined to add value to South Africa • South Africa’s best team • Market share at record levels • Output at record levels • New launch income the
Slide 49: Launch Income Value Generated
ASPEN IN THE SOUTH AFRICAN MARKET nch Income - Value Generated during June 2010 MAT Period 0-24 months Value r en o . o .. a s .. ze ti pr c C . In ve ne ar sp fi ed & -A ov P k A Ze ck M oc fi N ra er no dc la st M ip Sa A A C 49
Slide 50: South African Market Prospects
ASPEN IN THE SOUTH AFRICAN MARKET Prospects • Anticipate • Continued volume increases • Muted increase in SEP • Operationally • Further volume increases • Economies of scale to drive COGS reductions • Currency fluctuations • Affect operating profitability • ARV tender award • Increased lives • Margi
Slide 51: Sub-Saharan Africa (SSA)
SUB-SAHARAN AFRICA (SSA) • Current interest in Sub-Saharan Africa is in following broad categories Revenue from South Africa Exports R 94 m Shelys R267 m GSK Aspen Healthcare for Africa R549 m Total R910 m • Export from South Africa • Negatively affected by ARV genericisation • Commitment to procure
Slide 52: Sub-Saharan Africa: Shelys Africa
SUB-SAHARAN AFRICA (SSA) yls Africa - 12 Months to June 2010 • Shelys Pharmaceuticals (Tanzania) • Beta Healthcare (Kenya & Uganda) • Shelys Export (focus on southern / East Africa) • Disappointing trading period BETA • Private sales performance encouraging 49 • reps Focus on private market paying d
Slide 53: Sub-Saharan Africa: Aspen Healthcare for Africa
SUB-SAHARAN AFRICA (SSA) spen Healthcare for Africa - Financial Year 2010 • Rep force of 260 • Leverage representation FWCA 70 • Broader more relevant pipeline reps AWA R138m 90 reps R238m EA 70 reps • Dossiers in regulatory process R114m • Expect registration flow within twelve months StnA 30 reps
Slide 54: Global Products
GLOBAL PRODUCTS CYCLE REVENUE PROFIT CHARACTERISTICS Multinational distribution Base Base Business as usual Transition + + Volumes increase as distributors are loaded st transition - - Pipeline normalises, external distributors ke margin, Aspen distributors gear up Aspen control + + Product response
Slide 55: Global Products
GLOBAL PRODUCTS • Consists of GSK / Iroko products • GSK includes two transactions • ELIZ – Eltroxin, Lanoxin, Imuran and Zyloric • COSMOS – Alkeran, Leukeran, Purinethol, Kemadrin, Lanvis, Myleran, Septrin and Trandate • Cosmos included for just 7 months • On a like for like basis ELIZ products hav
Slide 56: Opportunities for Aspen Global: Eltroxin
OPPORTUNITIES FOR ASPEN GLOBAL Eltroxin • Unstable 50mcg / 100mcg • Stabilised the product • Developed 13 strengths • 12.5mcg / 25mcg / 50mcg / 75mcg / 88mcg / 100mcg / 112mcg / 125mcg / 135mcg / 150mcg / 174mcg / 200mcg / 300mcg • Bio batches in production • Worldwide market > USD1.7 billion • Braz
Slide 57: Aspen in Latam: Sales by Territory
ASPEN IN LATAM tam Sales by Territory 12 Months June 2010 : R1.2bn (6 Months to December 2009 : R500m) Venezuela 11% Mexico 16% Brazil 68% Chile 1% Argentina 1% Colombia 3% 57
Slide 58: Aspen in Latam
ASPEN IN LATAM • Sales R1 billion • Aspen ownership at 100% • Able to drive Aspen strategy • At half year we said • Incurred a loss in the region • Hoped to turn to profitability in these six months • Region not for the faint hearted • Hopeful our strategies would be successful • It is now profita
Slide 59: Aspen in Latam: Focus Areas
ASPEN IN LATAM Focus Areas • Increase our representation across the geography • Columbia, Chile, Ecuador, Peru and Argentina • Consolidate / entrench the gains made in Brazil, Mexico and Venezuela • Leverage our high fixed cost infrastructure • Introduction of organic pipeline • Product acquisitions
Slide 60: Aspen in Asia Pacific: Sales by Territory
ASPEN IN ASIA PACIFIC ales by Territory • Sales growth of 19% 12 Months to June 2010 : R1.5 billion (2009 : R1.2 billion) China 1% • Double digit growth for 9th Thailand 2% Taiwan 3% Other 7% Malaysia consecutive year 3% Indonesia 3% Philippines New 3% Zealand 4% • Australia – 67% of sales • Japan >
Slide 61: Aspen in Asia Pacific
ASPEN IN ASIA PACIFIC • Australia – headquarters for Asia Pacific • Expect Asia to be a meaningful contributor • Japan, Philippines, Indonesia, Thailand and Taiwan targeted • Organic growth opportunity in region • Utilisation of Aspen pipeline • From a zero base – sustained performance and meaningfu
Slide 62: Aspen in Asia Pacific: Australian Market Ranking
ASPEN IN ASIA PACIFIC ternational Operations No. of Rank Manufacturer % Share Scripts • Ranked 7 by volume of scripts th 1 GlaxoSmithKline 12,263,798 9.7% generated (excluding Generics) 2 Sanofi-Aventis 11,523,163 9.1% 3 Alphapharm 8,552,991 6.8% • Play an important role in providing 4Australia Pfiz
Slide 63: Aspen in Asia Pacific: Sigma
ASPEN IN ASIA PACIFIC Sigma • 98 Year history in the Australian market • Roots in wholesale • Diversified into Pharma • Pharma divisions comprise • Branded division – purchased / licensed IP • OTC including private labels • Generics – acquisitions of Arrow • Contract manufacture and exports • Sigma
Slide 64: Aspen in Asia Pacific: Sigma and Aspen
ASPEN IN ASIA PACIFIC igma and Aspen Rank Manufacturer No. of Scripts % Share • Potential to be ranked 1st by 1 2 Aspen/Sigma GlaxoSmithKline 15,293,805 12,263,798 12.13% 9.73% volume of scripts generated 3 Sanofi-Aventis 11,523,163 9.14% 4 Alphapharm 8,552,991 6.78% 5 Pfizer 8,544,862 6.78% 6 Astra
Slide 65: Why Sigma? Branded Business
ASPEN IN ASIA PACIFIC Why Sigma? BRANDED BUSINESS • The branded business is Sigma’s largest contributor to profitability • Aspen has a successful track record in this sector • Is the focus of the existing Aspen Australia business • Many of these brands are owned by Aspen in other geographies • Acqui
Slide 66: Why Sigma? OTC / Consumer and Generics
ASPEN IN ASIA PACIFIC Why Sigma? OTC / CONSUMER • Broader Aspen range • Leverage through compliant customers GENERICS • Regulated industry • Worldwide phenomena • Aspen has real expertise • Procurement • Pricing • Manufacturing • Pipeline • Product positioning • Capacity to drive the necessary COGS
Slide 67: Why Sigma? Manufacture and New Opportunities
ASPEN IN ASIA PACIFIC Why Sigma? MANUFACTURE • Assess best fit for individual products within the Aspen global manufacturing network • Manufacturing launch pad for Asia Pacific • Japanese approval • Exports to numerous Asia geographies NEW OPPORTUNITIES • Sigma channel provides access to broader gen
Slide 68: Why Sigma?
ASPEN IN ASIA PACIFIC Why Sigma? • We have a global manufacturing team • Ensure able to extract margin improvements • Across all divisions • We have a great team in Australia • Same team that started the operation in 2001 • Reps rated number 1 in Australia • Highly motivated • Will bring the necessa
Slide 69: Summary and Prospects: Summary
SUMMARY AND PROSPECTS Summary SOUTH AFRICA • Performed financially • Almost all areas • Cash flow generation continues to be our strength • South Africa firing • South Africa is a competitive manufacturing base • Favourable exchange rates INTERNATIONAL OPERATIONS • Global brands outperforming • Sub-
Slide 70: Summary and Prospects: Prospects
SUMMARY AND PROSPECTS Prospects • Anticipate sustained growth • Currency fluctuations will determine relative growth • In South Africa • Expect limited price increases • Increasing volumes and strong pipeline • In International • Sub-Saharan Africa will give improved performance • Asia Pacific to su
Slide 71: Generics Bulletin Report: May 2010
GENERICS BULLETIN REPORT : MAY 2010 nual Sales December 2009 Teva(1) Sandoz Mylan(2) Watson(3) (1) Sales exclude Ratiopharm; brand sales include Copaxone sales of USD2.83m Ratiopharm (4,5) (2) Generics sales growth was 9.2% Stada(4) (3) Includes Arrow from December 2009 Hospira(6) (4) Reported in Eu
Aspen Pharmacare Holdings — FY2010 Earnings Presentation on 6ix